文献速递血栓与止血

sutimlimab抑制经典补体途径治疗慢性免疫性血小板减少症的安全性与疗效

Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia.
PubMed 文献 · Blood Adv · 2023-01-01

这项1期研究评估了sutimlimab(抗C1s单克隆抗体)治疗对至少2种治疗反应不足的慢性/难治性免疫性血小板减少症患者的安全性和疗效。12例患者中5例(42%)获得持久血小板应答,4例达完全缓解;平均血小板计数从25×10^9/L升至54×10^9/L。研究认为C1s抑制可能是有益的治疗方法。

要点

  • sutimlimab治疗24小时后平均血小板计数从25×10^9/L升至54×10^9/L,A部分维持≥50×10^9/L。
  • 5例(42%)获持久血小板应答(随访≥50%时间≥50×10^9/L),4例达完全缓解(≥100×10^9/L)。
  • A部分74例次、B部分70例次治疗中出现不良事件;5例严重不良事件,1例(偏头痛)被研究者判定与sutimlimab相关。

核心结论

  • 在部分免疫性血小板减少症患者中,自身抗体激活经典补体途径加速血小板破坏或损害生成并导致治疗失败,C1s抑制可能是有益的治疗方法。

研究设计与样本

  • 1期研究(NCT03275454),纳入对至少2种治疗反应不足(血小板计数≤30×10^9/L)的慢性/难治性免疫性血小板减少症患者。
  • 12例患者(中位年龄42岁)接受每两周一次sutimlimab治疗,A部分中位治疗20.5周后中位洗脱2周。
  • B部分中12例符合条件患者中的7例接受sutimlimab再治疗,中位113周。

主要发现

  • A部分开始sutimlimab后24小时平均(标准差)血小板计数从25×10^9/L(17)升至54×10^9/L(60),A部分全程维持≥50×10^9/L。
  • 5例(42%)获持久血小板应答(随访≥50%时间血小板≥50×10^9/L),4例达完全缓解(血小板≥100×10^9/L)。
  • 洗脱期平均血小板计数回落至基线,B部分再治疗后升高;平均血小板计数改善伴随经典途径快速抑制。
  • A部分治疗中出现不良事件74例次(n=10),B部分70例次(n=6);5例严重不良事件,1例(偏头痛)被研究者判定与sutimlimab相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic/refractory immune thrombocytopenia (ITP) is a rare and pathophysiologically heterogeneous disorder with variable responsiveness to available treatments. Sutimlimab, a first-in-class humanized monoclonal anti-C1s IgG4 antibody, selectively inhibits the classical pathway. This phase 1 study (NCT03275454) assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of biweekly sutimlimab in patients with chronic/refractory ITP with an inadequate response to ≥2 therapies (platelet count ≤ 30 × 109/L). Twelve patients (median age 42 years) received sutimlimab for a median of 20.5 weeks followed by a median 2-week washout period (part A). In part B, 7 of the 12 eligible patients received sutimlimab retreatment for a median of 113 weeks. In part A, the mean (standard deviation) platelet count increased from 25 × 109/L (17) to 54 × 109/L (60) 24 hours after starting sutimlimab, maintaining ≥50 × 109/L throughout part A. Five patients (42%) achieved durable platelet count responses (≥50 × 109/L in ≥50% of follow-up visits) and 4 achieved complete response (platelet count ≥100 × 109/L). The mean platelet count returned to baseline during washout and increased upon retreatment in part B. The mean platelet count improvements accompanied the rapid inhibition of the classical pathway. There were 74 treatment-emergent adverse events in part A (n = 10) and 70 in part B (n = 6). Five serious adverse events were observed; 1 event (migraine) was assessed by the investigator as related to sutimlimab. These results demonstrated that in some patients with ITP, autoantibodies activate the classical complement pathway, accelerating platelet destruction or impairing platelet production and contributing to treatment failure. Thus, C1s inhibition may be a safe and beneficial therapeutic approach for patients with chronic/refractory ITP.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Broome CM, Röth A, Kuter DJ, et al. Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia. Blood Adv. 2023. PMID: 35973190. doi:10.1182/bloodadvances.2021006864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。